| Source: |
| Type: |
| Brain volume is a key biomarker in Alzheimer’s disease (AD) and is closely associated with the progression of the disease -AD is characterized by progressive brain shrinkage (atrophy) -Hippocampus: One of the earliest and most affected areas; crucial for memory formation. -Medial Temporal Lobe: Including the entorhinal cortex; important in converting short-term to long-term memory. -Parietal and Frontal Lobes: Atrophy spreads here as the disease progresses, affecting language, spatial awareness, and executive function. -MRI imaging is widely used to measure brain volume loss. -Rate of volume loss can predict cognitive decline and transition from: -Normal aging → Mild Cognitive Impairment (MCI) → Alzheimer’s Disease. Rate of Brain Volume Loss Population Group Estimated Brain Volume Loss / Year Healthy aging adults ~0.2–0.5% MCI patients ~1–2% AD patients ~2–3% or more |
| 4139- | Ex, | Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1372 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid